Hematopoietic expression of O6-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O6-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea

Hematopoietic expression of O⁶-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O⁶-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea

¹Indiana University Cancer Center and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN;
²Herman B Wells Center for Pediatric Research, Department of Pediatrics, The Riley Hospital for Children, Indianapolis, IN; and
³Division of Experimental Hematology, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH

Requests for Reprints: Leonard C. Erickson, I. U. Cancer Center, 1044 West Walnut Street, R4-151A, Indianapolis, IN 46202-5525. Phone: (317) 274-5202; Fax: (317) 274-8046. E-mail: lcericks{at}iupui.edu

Abstract

The major mechanism of tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is the DNA repair protein O⁶-methylguanine DNA methyltransferase (MGMT). This repair system can be temporarily inhibited by the free base O⁶-benzylguanine (BG), which depletes cellular MGMT activity and sensitizes tumor cells and xenografts to BCNU. In clinical studies, the combination of BG and BCNU enhanced the myeloid toxicity of BCNU, thereby reducing the maximum tolerated dose. We have shown previously that retroviral expression of the P140K mutant of MGMT (MGMT-P140K) in murine and human hematopoietic cells produces significant resistance of bone marrow cells to low-dose, combination BG and BCNU treatment in vivo. In the current study, we investigated the ability of bone marrow transplantation with MGMT-P140K-transduced hematopoietic cells to protect against an intensive antitumor treatment regimen of combination BG and BCNU in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. The donor marrow cells underwent in vivo BG and BCNU selection before transplantation, allowing infusion of a highly selected population of transduced cells. Tolerance to the intensive BG and BCNU treatment was markedly improved in secondary MGMT-P140K-transplanted mice (n = 19) compared to untransplanted mice (n = 15), as indicated by blood counts and survival rate. The dose-intensified BG and BCNU therapy produced significant growth delays of glioma xenografts in MGMT-P140K-transplanted mice, extending the tumor doubling time by >40 days. These results demonstrate that MGMT-P140K-transduced bone marrow protects against BG and BCNU combination therapy in vivo and allows dose-intensified treatment of tumor xenografts.

Keywords:

Footnotes

↵2 Unpublished observations.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Grant support: NIH Grant P01 CA75426 (L.C.E. and D.A.W.).
- Accepted September 10, 2003.
- Received May 21, 2003.
- Revision received July 18, 2003.
American Association for Cancer Research